The Truth Is Out There

Archive for October, 2026

NIH Funds Mutant Experiments Involving One of the Deadliest Pathogens


The federal grant, titled Evaluating how BipA contributes to Yersinia pestis pathogenesis during pneumonic plague, explicitly identifies bacterial mutants as part of the experimental research.

The proposed work includes laboratory testing, examination of biological samples, and mouse infection experiments.

The experiments concern BipA, a bacterial protein associated with resistance to immune defenses, attachment to mammalian cells, and virulence.

The award establishes federal funding for experiments using mutant plague bacteria.

Whether researchers will generate additional mutants or use previously constructed ones is a question for the underlying experimental records.

The physical activity being financed involves experimentally altered bacteria identified as the cause of plague, tested for biological characteristics relevant to infection and disease.

NIH Admits Plague Protein Helps Defeat Immune Defenses

The federal grant identifies BipA as a bacterial virulence factor involved in:

“subverting host defense strategies during pneumonic plague.”

NIH reports preliminary findings connecting BipA to bacterial resistance against neutrophils and bactericidal permeability-increasing protein (BPI).

Neutrophils are immune cells involved in eliminating bacterial threats.

BPI is a host-defense protein that recognizes bacterial lipopolysaccharide, commonly called endotoxin.

According to the grant, BipA also influences bacterial attachment to mammalian cells and regulates additional proteins following BPI exposure.

The funded experiments therefore target a biological system NIH already associates with the plague bacterium’s ability to withstand immune defenses.

Researchers Will Investigate Plague Virulence Through Experimental Infections

The grant identifies proteins regulated by BipA as potential contributors to virulence, the organism’s capacity to cause disease.

Researchers propose using bacterial mutants and experimental infection models to investigate how BipA affects resistance to host defenses and interactions with mammalian cells.

The experimental objectives include determining whether the resistance observed in preliminary research also operates during infection in living animals.

NIH is financing experiments that connect mutant plague bacteria, immune resistance, and the biological mechanisms underlying disease severity.

  • What independent evidence establishes how the mutants’ virulence will compare with their starting strains, and what safeguards govern experiments if increased resistance or virulence is observed?

Federal Funding Extends the Mutant Plague Experiments Through 2028

The $223,957 award began September 2, 2026, and extends through August 31, 2028.

The grant identifies the proposed experimental activities and reports preliminary findings involving immune resistance and bacterial virulence.

The public award summary does not provide the complete experimental protocol, mutant inventory, independent biosafety evaluation, or containment procedures.

Those records are consequential because the biological characteristics of the mutants determine the risks associated with laboratory handling, experimental infection, and accidental exposure.

The central oversight issue is who independently evaluates the biological consequences of the experimental modifications and verifies safeguards before the research proceeds.

Bottom Line

NIH awarded East Carolina University $223,957 for experiments using mutant plague bacteria, acknowledging in the same grant that the organism is among the deadliest pathogens known to man.

The government’s own project description identifies bacterial resistance to immune defenses, mammalian-cell attachment, and virulence as central research subjects.

The award establishes plans to use bacterial mutants and experimental infections.

The outcomes of experiments conducted under this new funding remain to be determined from subsequent records.

  • What mutant plague bacteria will federal funding support, what changes in immune resistance and virulence will the experiments produce, and who independently verifies that the risks to laboratory workers and the public are adequately controlled?

NIH Pays East Carolina University to Mutate Plague Bacteria: ‘One of the Deadliest Pathogens Known to Man’


$223,957 federal grant explicitly funds Yersinia pestis bacterial mutants and experimental infections involving the mechanisms allowing plague to overcome immune defenses and contribute to virulence.

Composite image showing the National Institutes of Health’s September 2, 2026, plague-research grant R21AI192340, its description of Yersinia pestis as “one of the deadliest pathogens known to man,” and microscopy imagery of bacteria identified as Y. pestis alongside immune cells.

The National Institutes of Health (NIH) awarded East Carolina University $223,957 on September 2, 2026, for experiments using mutant plague bacteria to investigate mechanisms of immune resistance and virulence, according to federal grant R21AI192340, administered by the National Institute of Allergy and Infectious Diseases (NIAID).

The agency explicitly acknowledges:

“Yersinia pestis is one of the deadliest pathogens known to man.”

Yet the same federal award declares:

“we will use bacterial mutants”

The grant authorizes research through August 31, 2028, involving laboratory experiments and experimental infections in mice to investigate how plague bacteria resist immune defenses and contribute to disease.

The federal government is financing experiments involving mutant plague bacteria while acknowledging that its research subject is among the deadliest pathogens known to humanity.

The award raises urgent questions:

  • What plague-bacteria mutants will researchers create or use, and what biological changes could result?
  • Could any mutants exhibit increased resistance to immune defenses or greater virulence?
  • Who independently evaluates the risks of experiments involving an organism NIH itself describes as exceptionally deadly?
  • What containment safeguards, emergency procedures, and informed-consent protections apply to laboratory personnel?
  • What independent oversight protects surrounding communities from accidental exposure?

The findings come after JonFleetwood.com reported on October 16 that NIH awarded Stanford University $782,082 to develop experimental influenza vaccine formulations that activate TLR4, the immune receptor stimulated by bacterial endotoxin (LPS), including a formulation containing a synthetic compound modeled on the inflammatory component of endotoxin.

You can contact NIH here.

Screenshot of NIH grant R21AI192340, awarded September 2, 2026, to East Carolina University for $223,957, showing the federal agency’s description of Yersinia pestis as “one of the deadliest pathogens known to man” and its proposal to use bacterial mutants in experiments investigating immune resistance and virulence.

San Diego Drops Enterotoxin-Producing Bacterial Spores and Insecticidal Toxins From Helicopters Despite Inhalation Warnings and Past Unannounced Release


County claims pesticides are harmless despite documented lung inflammation, unresolved toxicity concerns, and releases without residents’ consent.

Investigative graphic combining San Diego County’s helicopter mosquito-control program with VectoMax FG’s EPA-registered label, a 2010 study documenting persistent lung inflammation in mice exposed to related bacterial pesticide aerosols, and a 2020 European Food Safety Authority finding that the bacterial strain AM65-52 can produce enterotoxins. The manufacturer also warns that VectoMax FG is harmful if inhaled.

San Diego County’s 2026 aerial mosquito-control schedule identifies an October 29 helicopter operation involving biological pesticides containing bacterial spores and insecticidal toxins, despite manufacturer inhalation warnings, experimental findings of persistent lung inflammation, and a documented 2019 incident in which beachgoers reportedly witnessed an unexpected helicopter release of the same commercial pesticide near Camp Pendleton.

The county lists up to 54 potential treatment locations covering approximately 1,400 acres, including parks, lagoons, rivers, and other waterways.

Yet officials assure the public that the bacterial pesticides:

“don’t harm people, pets, plants, or wildlife.”

The manufacturer’s labeling warns that VectoMax FG is harmful if inhaled, while European regulators could not complete an inhalation risk assessment for residents and bystanders involving one of its bacterial strains.

  • Who authorized the deliberate distribution of bacterial spores and insecticidal toxins near public areas without obtaining individual residents’ consent?
  • What advance notification protects people from unexpectedly encountering these releases?
  • Who independently established the safety of the complete formulations?
  • And what physical measurements show whether airborne biological material reaches neighboring properties?

These questions are particularly consequential because an earlier helicopter release of VectoMax FG reportedly caught beachgoers unaware, prompting concerns about notification and a commitment to publicize future schedules.

San Diego County Vector Control Program webpage detailing recurring helicopter applications of mosquito larvicides into standing water across the county. The agency confirms aerial treatments occur every three to four weeks during mosquito season, with posted signs and optional email notifications for the public. Source: San Diego County, “Aerial Mosquito Larvicide Treatments.”

San Diego County’s official 2026 aerial pesticide treatment schedule lists 11 rounds of helicopter operations from March 24 through October 29, including multiple two-day operations. The county says treatment dates may change depending on conditions. Source: San Diego County Vector Control Program.


Beachgoers Reported Unexpected Helicopter Release in 2019

A 2019 San Clemente Times investigation, titled Mosquito Battleground: Camp Pendleton to Post Schedule Following Midday Larvicide Drop at Lower Trestles, documented public concerns after a helicopter released VectoMax FG near Lower Trestles and San Onofre.

According to the report, people on the beach and nearby trail were unaware that the operation would occur.

Witnesses described seeing brown material released from the aircraft “without warning.”

They questioned why people using the surrounding public areas had not received advance notice.

Camp Pendleton officials described the material as non-toxic, and the incident prompted a commitment to post future application schedules.

The account documents an actual release, public surprise, and a notification dispute. It does not report confirmed adverse health effects.

The central revelation is that people reportedly encountered an intentional biological-pesticide dispersal operation without knowing it was coming.

The 2019 operation involved Camp Pendleton, whereas the October 29, 2026, schedule belongs to San Diego County’s separate Vector Control Program.

Nevertheless, both records concern helicopter distribution of VectoMax FG in the San Diego region.

  • What evidence establishes that public notification now reaches everyone potentially exposed, rather than only people who have subscribed to alerts or encountered posted signs?

May 2, 2019, San Clemente Times investigation reporting on an April 19 helicopter larvicide drop at Lower Trestles near Camp Pendleton that caught beachgoers unaware. Former professional surfer Yadin Nicol said the helicopter was “just dumping without any warning,” raising concerns about public notification before aerial pesticide releases.

Manufacturer Warns Biological Pesticide Is Harmful if Inhaled

San Diego County identifies VectoMax FG, manufactured by Valent BioSciences, among its aerial mosquito-control products.

The manufacturer’s EPA-registered label states:

“Harmful if absorbed through the skin or inhaled.”

It also warns:

“Avoid breathing dust.”

And:

“Repeated exposure to high concentrations of microbial proteins can cause allergic sensitization.”

The formulation contains:

  • 2.7% Bacillus sphaericus fermentation solids, spores, and insecticidal toxins.
  • 4.5% Bacillus thuringiensis israelensis fermentation solids, spores, and insecticidal toxins.
  • 92.8% other ingredients, individually unidentified on the public label.

Certain workers handling or applying the product must wear respiratory protection.

The manufacturer acknowledges inhalation hazards from the formulated material while San Diego County assures residents the bacterial pesticides are harmless.

  • What finished-product testing establishes whether airborne dust, bacterial spores, or toxins can reach members of the public during actual helicopter applications?

VectoMax FG manufacturer’s EPA-registered product label identifies bacterial fermentation solids, spores, and insecticidal toxins as active ingredients, with 92.8% listed as other ingredients. The label warns that the product is “harmful if absorbed through the skin or inhaled,” instructs users to avoid breathing dust, and requires respiratory protection for certain applicators.

VectoMax FG manufacturer’s EPA-registered label, Section 2, “Precautionary Statements,” warns that the bacterial pesticide is “harmful if absorbed through the skin or inhaled,” instructs users to avoid breathing dust, and requires N95-equivalent or stronger respiratory protection for certain workers. It also warns that repeated exposure to concentrated microbial proteins can cause allergic sensitization and prohibits application directly to finished drinking-water reservoirs intended for human consumption.

Scientists Found Lung Inflammation 70 Days After Exposure

A 2010 study published in BMC Microbiology exposed mice to commercial Bacillus thuringiensis pesticide aerosols, including a Bti product.

Researchers found interstitial lung inflammation in three of 17 mice examined 70 days after exposure.

They concluded:

“Repeated low dose aerosol exposures to commercial Bt based biopesticides can induce sub-chronic lung inflammation in mice”

The researchers also reported that exposure produced no apparent immediate airway irritation despite the later findings.

Their experiment involved aerosolized pesticide preparations, whereas San Diego describes helicopter deployment of granules into standing water.

That difference creates an important empirical question.

  • What physical measurements establish how much inhalable material the granular deployment actually generates?

2010 peer-reviewed study in BMC Microbiology documenting persistent lung inflammation in mice exposed to commercial Bacillus thuringiensis biopesticides. Researchers observed interstitial lung inflammation 70 days after exposure and reported that inhalation produced no immediate airway irritation despite subsequent inflammatory findings.

2010 [http://2010 BMC Microbiology study conclusion warns that repeated inhalation of Bacillus thuringiensis pesticide aerosols may contribute to severe lung disease, while producing no immediate airway irritation to warn exposed individuals. Researchers described the potentially unnoticed exposure as “insidious” and called for further studies of long-term respiratory effects.]BMC Microbiology study conclusion warns that repeated inhalation of Bacillus thuringiensis pesticide aerosols may contribute to severe lung disease, while producing no immediate airway irritation to warn exposed individuals. Researchers described the potentially unnoticed exposure as “insidious” and called for further studies of long-term respiratory effects.

Figure 5, 2010 BMC Microbiology study: Microscopic images of mouse lung tissue 70 days after exposure to commercial Bacillus thuringiensis biopesticides. Arrows identify areas of interstitial inflammation, including findings in three of 17 mice repeatedly exposed to VectoBac aerosols. The study documents persistent inflammatory changes in lung tissue following experimental pesticide exposure.

European Regulators Could Not Resolve Inhalation, Enterotoxin, & Genotoxicity Concerns

The European Food Safety Authority’s 2020 peer review examined Bti strain AM65-52, the same strain identified in VectoMax FG.

EFSA stated:

“The potential concern for serious health effects after repeated exposure by inhalation could not be excluded”

It also identified unresolved questions concerning potential genotoxicity from bacterial Cry proteins through non-dietary exposure.

Its finding concerning public exposure was explicit:

“the risk assessment by inhalation for residents and bystanders cannot be concluded”

The review confirms:

“Bacillus thuringiensis ssp. israelensis (serotype H-14) strain AM65-52 has been shown to be able to produce enterotoxins”

The assessment concerned greenhouse applications rather than San Diego’s helicopter operations.

What studies of the complete finished formulation and actual aerial-distribution conditions resolve these toxicological questions for people near the treatment sites?

November 12, 2020, European Food Safety Authority (EFSA) peer review of Bacillus thuringiensis israelensis strain AM65-52, used in VectoMax FG. Regulators identified the strain’s ability to produce enterotoxins, unresolved potential genotoxicity, and repeated-inhalation concerns, concluding that the inhalation risk assessment for residents and bystanders could not be completed.

EPA Says Bti Is Harmless as Its Registered Product Carries Inhalation Warnings

The U.S. Environmental Protection Agency’s Bti mosquito-control guidance states:

“Bti has no toxicity to people”

EPA says registered Bti products do not pose a human health risk when used as directed and that residents need not leave treated areas.

Yet the EPA-registered VectoMax FG label identifies inhalation hazards, while EFSA’s assessment identified unresolved repeated-inhalation concerns for its Bti strain.

The issue is the scientific foundation of the competing regulatory statements.

  • Which physical tests and exposure measurements establish safety for nearby residents during helicopter deployment of the complete granular formulation?
  • And have those findings been independently verified under conditions resembling actual field operations?

San Diego Residents Can Contact County Officials

Residents seeking answers about helicopter distribution of bacterial spores and insecticidal toxins can contact the San Diego County Vector Control Program at 858-694-2888 or vector@sdcounty.ca.gov, and the County Board of Supervisors at 619-531-5600 or PublicComment@sdcounty.ca.gov.

Pesticide safety or application complaints can be directed to the San Diego County Pesticide Regulation Program at 858-694-8980 or PRP.AWM@sdcounty.ca.gov, or the California Department of Pesticide Regulation at 1-877-378-5463.

Residents can request the identities and quantities of materials scheduled for release, independent airborne-exposure measurements, the evidence supporting public safety assurances, and an explanation of notification and consent procedures.

Bottom Line

San Diego County is preparing another helicopter operation involving bacterial spores and insecticidal toxins without obtaining individual residents’ consent.

Despite documented inhalation warnings and a 2019 release near Camp Pendleton that reportedly caught beachgoers unaware.

The manufacturer warns that VectoMax FG is harmful if inhaled.

Experimental researchers documented persistent lung inflammation following exposure to related pesticide aerosols.

European regulators identified the bacterial strain’s ability to produce enterotoxins and unresolved inhalation and genotoxicity concerns.

Yet EPA and county officials assure the public that these biological pesticides are safe, while San Diego relies on posted signs and optional email notifications rather than individual consent.

  • Who independently verifies what biological material reaches surrounding properties, what physical evidence establishes the safety of the complete formulation, and who authorized these releases without residents’ consent?
  • And after beachgoers previously encountered a helicopter release without warning, what guarantees that affected communities will receive meaningful advance notice before the next operation?

Children’s Hospital of Philadelphia Injected 2,054 Children With Flu Vaccines Under Anesthesia—Now Eyes COVID Shots. This Is Absolutely Disgusting.


CHOP uses the time pressures of pediatric surgery to excuse curtailed informed-consent discussions, as one-third of participating families said their children otherwise would have gone unvaccinated.


Children’s Hospital of Philadelphia’s May 20, 2026, disclosure reveals plans to expand its program for vaccinating children under anesthesia to include COVID-19 and RSV shots, raising further concerns about vaccine safety, parental informed consent, and the use of surgical procedures to increase vaccination rates.

A May 20, 2026, Children’s Hospital of Philadelphia (CHOP) disclosure reveals that the hospital administered 2,054 influenza vaccine doses to children under sedation or anesthesia during the 2025–2026 flu season through a program called “Close Your Eyes, We’ll Immunize” and is now exploring COVID-19 and other injections during medical procedures.

The hospital admits that approximately one-third of participating families said their children otherwise would have gone unvaccinated.

It also cites limited time before surgery as an obstacle to discussing parental concerns about vaccination.

Which raises questions:

  • Why is a hospital using children’s surgical appointments to increase vaccination rates?
  • Why are time pressures being offered as an excuse for limiting discussions about vaccine risks?
  • Who independently verifies informed consent and monitors adverse reactions when children receive injections under anesthesia?

The hospital’s own disclosures establish a disturbing arrangement.

Children are brought in for medical procedures, their unconsciousness becomes an opportunity for additional injections, and the institution measures success by how many vaccines it administers.

You can contact CHOP here.

Children’s Hospital of Philadelphia’s May 20, 2026, newsletter reveals that its “Close Your Eyes, We’ll Immunize” program was designed to increase influenza vaccination rates by administering injections to children under sedation or anesthesia during medical procedures.
Children’s Hospital of Philadelphia admits measuring the success of its vaccination-under-anesthesia program by the number of injections administered, reporting 2,054 influenza vaccine doses during the 2025–2026 season and revealing that approximately one-third of participating families said their children otherwise would have gone unvaccinated.

Technically Speaking “close Your Eyes, We’ll Immunize” — A Chop Initiative To Improve Influenza Vaccines!